Ramucirumab as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib: Patient-focused outcome results from the randomised phase III REACH study (vol 81, pg 17, 2017)

Affiliation auteurs!!!! Error affiliation !!!!
TitreRamucirumab as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib: Patient-focused outcome results from the randomised phase III REACH study (vol 81, pg 17, 2017)
Type de publicationJournal Article
Year of Publication2018
AuteursChau I, Peck-Radosavljevic M, Borg C, Malfertheiner P, Seitz JFrancois, Park JOh, Ryoo B-Y, Yen C-J, Kudo M, Poon R, Pastorelli D, Blanc J-F, Chung HCheol, Baron AD, Okusaka T, Bowman L., Cui ZLin, Girvan AC, Abada PB, Yang L, Zhu AX
JournalEUROPEAN JOURNAL OF CANCER
Volume100
Pagination135-136
Date PublishedSEP
Type of ArticleCorrection
ISSN0959-8049
DOI10.1016/j.ejca.2018.06.002